novo nordisk's semaglutide failed to slow alzheimer's disease progression An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, the of in closely watched trials, Nordisk said. https://cnn.it/4ohnWx8 AD/PD 2026: Novo Nordisk's semaglutide

This article outlines an approach to interpreting and working up a high serum B12 in adults by separating four possibilities: intake-related elevation, disease-associated hypercobalaminemia (an elevated blood B12 associated with an underlying condition), analytical interference, and functional deficiency

Population-based cohorts and nomogram models that incorporate variables such as age, BP, and hematoma volume provide refined prognostic insights 95

N Engl J Med 375:18341844 Garvey WT, Frias JP, Jastreboff AM et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Healthcare providers must weigh the benefits against potential risks for each patient